Bristol-Myers Squibb Company (AKA: BMS, ) Profile last edited on: 5/19/2016
NO Business Identifier is currently available for this company. Year Founded
1887Last Involved Year
2022Key People / Management
John R Beecham -- Senior Director, Business
Albert B Bianchi -- Associate Director, Licen
Graham R Brazier -- Vice President, Business
Michael Cucolo --
Mark Dennish -- Sr. Director Corporate Bu
Wendy Dixon --
Mark W Durand --
Cindy Ehrenfreund -- Director, Specialty Pharm
Craig A Funt -- Executive Director
Patrick Gallagher --
David George --
Joseph L Glajch -- Director, Business Develo
Stephen B Haber --
Eric L Hagestad -- Sr. Director, Licensing
James Hanly -- Associate Director, Exter
Jason Haviland -- Associate Director, Busin
Timothy F Herpin --
Tamar Howson -- Senior Vice President - C
Mamoun M Hussein -- Associate Director-Extern
Jacqueline J Kim --
Gary A King -- Senor Director, Licensing
Janusz W Kostanski --
Peter B Kramer --
Karen LaRochelle -- Director, Business Develo
Paul Leijten -- Director, Licensing
Snjezana Lelas --
Charles Linzner -- Vice Pres. & Senior Couns
Ang�le Maki -- Director, Strategic Trans
James A McCarthy -- Director, External Develo
Courtney E Radosti -- Project Manager
Chandra Ramanathan -- Senior Research Investiga
Arlene Stark --
Mary Jo Struttmann -- Business Development
Scott T Taylor --
Susan Vaughn -- Director, External Develo
David D Voelz -- Director Business Operati
Kristen L Von Seggern -- Director, US Business Dev
Lotte Wang -- Director, Licensing
John Wasylyk --
Marcia D Woods -- Director, Oncology/ Pharm
Albert B Bianchi -- Associate Director, Licen
Graham R Brazier -- Vice President, Business
Michael Cucolo --
Mark Dennish -- Sr. Director Corporate Bu
Wendy Dixon --
Mark W Durand --
Cindy Ehrenfreund -- Director, Specialty Pharm
Craig A Funt -- Executive Director
Patrick Gallagher --
David George --
Joseph L Glajch -- Director, Business Develo
Stephen B Haber --
Eric L Hagestad -- Sr. Director, Licensing
James Hanly -- Associate Director, Exter
Jason Haviland -- Associate Director, Busin
Timothy F Herpin --
Tamar Howson -- Senior Vice President - C
Mamoun M Hussein -- Associate Director-Extern
Jacqueline J Kim --
Gary A King -- Senor Director, Licensing
Janusz W Kostanski --
Peter B Kramer --
Karen LaRochelle -- Director, Business Develo
Paul Leijten -- Director, Licensing
Snjezana Lelas --
Charles Linzner -- Vice Pres. & Senior Couns
Ang�le Maki -- Director, Strategic Trans
James A McCarthy -- Director, External Develo
Courtney E Radosti -- Project Manager
Chandra Ramanathan -- Senior Research Investiga
Arlene Stark --
Mary Jo Struttmann -- Business Development
Scott T Taylor --
Susan Vaughn -- Director, External Develo
David D Voelz -- Director Business Operati
Kristen L Von Seggern -- Director, US Business Dev
Lotte Wang -- Director, Licensing
John Wasylyk --
Marcia D Woods -- Director, Oncology/ Pharm
Location Information
345 Park Avenue
New York, NY 10154
New York, NY 10154
| (212) 546-4000 |
| www.bms.com |
Public Profile
Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical need, such as affective (psychiatric) disorders, Alzheimer?s/dementia, cardiovascular (primarily atherosclerosis/thrombosis), diabetes, hepatitis, HIV/AIDS, obesity, oncology, rheumatoid arthritis and related diseases, and solid organ transplant. Its products include PLAVIX for protection against fatal or non-fatal heart attack or stroke, and AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; REYATAZ and SUSTIVA Franchise for the treatment of HIV, and BARACLUDE for the treatment of chronic hepatitis B infection; ERBITUX, SPRYCEL, and IXEMPRA for treating oncology related diseases; ABILIFY, a medicine for the treatment of mental illness; ORENCIA, a medicine for rheumatoid arthritis; and ONGLYZA for the treatment of type 2 diabetes. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, belatacept, brivanib, dapagliflozin, ipilimumab, necitumumab, and XL-184. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has various alliances and collaborations with sanofi-aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer Inc.; Exelixis, Inc.; ZymoGenetics, Inc.; and Alder Biopharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
